当部案内
技術支援室

TOP > 当部案内 > 技術支援室

技術支援室では、臨床研究等で得られた貴重な検体の処理及び保管管理、並びに当該検体を利用した新たな研究企画及び実施をしております。

REBIND事業の
サポート

COVID-19に関する
研究の推進・支援

外部機関と連携した
研究推進・支援

連携機関

スタッフ紹介

更新日:2022年12月15日

役職 名前
技術支援室室長(併任) 木村 基, Moto KIMURA
上級研究員 竹内(柴田)潤子, Junko S. TAKEUCHI
上級研究員 深野 顕人, Kento FUKANO
特任研究員 神川 あずさ, Azusa KAMIKAWA
特任研究員 鬼頭 優美子, Yumiko KITO
研究補助員 有吉 希, Nozomi ARIYOSHI
研究補助員 波田野 恵美子, Emiko HATANO
研究補助員 髙橋 杏奈, Anna TAKAHASHI
事務助手 田村 良子, Ryoko TAMURA

実績

出版論文(技術支援室発足以降)

出版論文(査読付論文誌)

  • [1] Neutralizing antibodies following three doses of BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron predominant wave.
    Yamamoto, S., K. Matsuda, K. Maeda, K. Horii, K. Okudera, Y. Oshiro, N. Inamura, J. S. Takeuchi, M. Konishi, M. Ozeki, T. Mizoue, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura, and N. Ohmagari. 2023.
    Int J Infect Dis. 2023 Jan 21 : S1201-9712(23)00023-1.
    https://doi.org/10.1016/j.ijid.2023.01.023.

  • [2] SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study.
    Takeuchi, J. S., A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, M. Kimura, A. Kamikawa, Y. Kito, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, H. Mitsuya, N. Ohmagari, and W. Sugiura (2022).
    Scientific Reports 12 (1): 15447.
    https://doi.org/10.1038/s41598-022-19581-y

  • [3] Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination.
    Okumura, N., S. Saito, Y. Takamatsu, J. S. Takeuchi, Y. Asai, M. Sanada, N. Iwamoto, K. Maeda, H. Mitsuya, and N. Ohmagari (2022).
    J Infect Chemother 28 (12): 1704-1706.
    https://doi.org/10.1016/j.jiac.2022.08.026

  • [4] Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA).
    Terayama, Y., N. Tomita, J. Terada-Hirashima, Y. Uemura, Y. Shimizu, J. S. Takeuchi, Y. Takamatsu, K. Maeda, A. Mikami, M. Ujiie, and W. Sugiura (2022).
    Life (Basel) 12 (7).
    https://doi.org/10.3390/life12070966

  • [5] Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
    Okumura, N., S. Tsuzuki, S. Saito, S. I. Hattori, J. S. Takeuchi, T. Saito, M. Ujiie, M. Hojo, N. Iwamoto, W. Sugiura, H. Mitsuya, and N. Ohmagari (2022).
    J Infect Chemother 28 (9): 1340-1343.
    https://doi.org/10.1016/j.jiac.2022.04.018

  • [6] An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
    Khor, S. S., Y. Omae, J. S. Takeuchi, A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, M. Kimura, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, H. Mitsuya, N. Ohmagari, W. Sugiura, and K. Tokunaga (2022).
    Vaccines (Basel) 10 (4).
    https://doi.org/10.3390/vaccines10040563

  • [7] Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
    Miyazato, Y., K. Yamamoto, Y. Nakaya, S. Morioka, J. S. Takeuchi, Y. Takamatsu, K. Maeda, M. Kimura, W. Sugiura, H. Mitsuya, M. Yano, and N. Ohmagari (2022).
    J Infect Chemother 28 (7): 991-994.
    https://doi.org/10.1016/j.jiac.2022.03.002

  • [8] Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Yamamoto, S., A. Fukunaga, A. Tanaka, J. S. Takeuchi, Y. Inoue, M. Kimura, K. Maeda, G. Ueda, T. Mizoue, M. Ujiie, W. Sugiura, and N. Ohmagari (2022.)
    Vaccine 40 (13): 1924-1927.
    https://doi.org/10.1016/j.vaccine.2022.02.052

  • [9] Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
    Yamamoto, S., K. Maeda, K. Matsuda, A. Tanaka, K. Horii, K. Okudera, J. S. Takeuchi, T. Mizoue, M. Konishi, M. Ozeki, H. Sugiyama, N. Aoyanagi, H. Mitsuya, W. Sugiura, and N. Ohmagari (2022).
    Clin Infect Dis 75 (1): e683-e691.
    https://doi.org/10.1093/cid/ciab1048

preprint

お問い合せ
臨床研究センター 産学連携推進部
技術支援室:


REBIND事業事務局: